UT Southwestern registers Phase 1/2 trial pairing tegavivint with Exelixis' zanzalintinib in HCC
A new investigator-sponsored study will test the combination in liver cancer patients with Wnt pathway mutations who have not yet received VEGFR-targeted TKIs.
This week brought one new trial registration involving the company as a collaborator.
- A Phase 1/2 study titled "Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma" was listed on 2026-10-16 and is not yet recruiting. The trial is sponsored by University of Texas Southwestern Medical Center with Iterion Therapeutics and Exelixis listed as collaborators1. The study will enroll patients with advanced hepatocellular carcinoma and Wnt pathway mutations (CTNNB1, AXIN1, CREBBP, APC) who have progressed after at least one prior line of systemic therapy and have not previously received VEGFR-targeted tyrosine kinase inhibitors1. The design begins with a dose escalation phase using a Bayesian Optimal Interval (BOIN) design with cohorts of 3 to 6 participants per dose level to assess safety and tolerability1, enrolling an estimated 36 participants total, with an estimated start date of 2026-12-01.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.